Acquired Partial Lipodystrophy Medication

Updated: Feb 11, 2020
  • Author: George T Griffing, MD; Chief Editor: George T Griffing, MD  more...
  • Print

Medication Summary

Pharmacologic intervention is limited in acquired partial lipodystrophy. [32, 33, 35] Biguanides and thiazolidinediones have been used in the treatment of the insulin-resistant state (which includes type 2 diabetes and polycystic ovary disease) and in cases of HIV–related glucose intolerance. Although not studied in this group of patients, these drugs should be the first line of treatment if diabetes occurs. Fibrates are the drug of choice for the treatment of hypertriglyceridemia and low HDL cholesterol syndrome.


Hypoglycemic agents

Class Summary

These medications would be started if the patient has developed diabetes that is not being controlled through diet. Insulin sensitizers (biguanides and thiazolidinediones) can be used to reduce insulin levels in women with polycystic ovarian syndrome and with irregular periods.

Metformin (Glucophage)

Reduces hepatic glucose output, decreases intestinal absorption of glucose, and increases glucose uptake in peripheral tissues (muscle and adipocytes). Major drug used in type 2 diabetes and obesity.

Pioglitazone (Actos)

Improves target cell response to insulin without increasing insulin secretion from pancreas. Decreases hepatic glucose output and increases insulin-dependent glucose use in skeletal muscle and possibly in liver and adipose tissue.